Search results for "Topic"

The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC

2013

The Biopharmaceutics Classification System (BCS) has found widespread utility in drug discovery, product development and drug product regulatory sciences. The classification scheme captures the two most significant factors influencing oral drug absorption; solubility and intestinal permeability and it has proven to be a very useful and a widely accepted starting point for drug product development and drug product regulation. The mechanistic base of the BCS approach has, no doubt, contributed to its wide spread acceptance and utility. Nevertheless, underneath the simplicity of BCS are many detailed complexities, both in vitro and in vivo which must be evaluated and investigated for any given…

Patterns and trends in scientific research on generic drugs

2016

[Purpose]: The purpose of this study to investigate the evolution and current status of peer-reviewed publications concerning generic drugs during the past few decades. [Methods]: Scientific articles about generic drugs published until 2012 were retrieved through the PubMed/MEDLINE database, and a content analysis was performed. [Findings]: Our study revealed an increasing number of publications on generics since 1984. Statins, antiretroviral therapies, and antiepileptics, followed by immunosuppressants and antithrombotic agents, were the most common therapeutic drug categories. [Implications]: Almost 60% of the generics detailed in studies indexed in MEDLINE were acting on the cardiovascul…

Asthma Control: The Right Inhaler for the Right Patient

2015

Inhaled therapy is the cornerstone of asthma management in that it optimizes the delivery of the medication to the site of action. The effectiveness of inhaled therapy is affected by the correct choice of the device and proper inhalation technique. In fact, this influences the drug delivery and distribution along the bronchial tree, including the most peripheral airways. In this context, accumulating evidence supports the contribution of small airways in asthma, and these have become an important target of treatment. In reality, the “ideal inhaler” does not exist, and not all inhalers are the same. Advances in technology has highlighted these differences, and have led to the design of new d…

Residents'corner April 2014. Editorial: what's new this month?

2014

In this issue of the European Journal of Dermatology, Bircher et al.[1] revisit tolerance induction in drug hypersensitivity reactions, which is a controversial issue, particularly in delayed hypersensitivity reactions. Drug hypersensitivity may present as a mild, moderate or severe life-threatening reaction, becoming a problem for many patients when the offending drug is essential (and even irreplaceable).Determining which drug is responsible for the reaction may be challenging, especially in multiple [...]

Minimum effective dose for antidepressants - an obligatory requirement for antidepressant drug evaluation?

1996

Extensive clinical trials are required for registration and approval of new antidepressants in most countries including the requirement that a minimal effective dose should be determined. The rationale for this requirement is to avoid the use of unnecessarily high doses. The implication is that for every antidepressant, a dose exists that serves as a threshold, below which all doses are not effective or are clearly less effective in treating a major depressive episode. Dose titration and fixed dose studies are used to determine the minimal effective dose, but both strategies have limitations and often do not allow definite establishment of a clear-cut minimal effective dose. The effort of e…

Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.

2007

The ubiquitin-proteasome pathway is the main proteolytic system present in the nucleus and cytoplasm of all eukaryotic cells. Apoptosis activation induced by ubiquitin-proteasome pathway inhibition makes the proteasome a new target of anticancer therapy. Bortezomib is the first proteasome inhibitor to be approved by the US FDA; in 2003 as a third line and in 2005 as a second line therapy for the treatment of multiple myeloma only. This review focuses on the use of bortezomib, not only in its therapeutic role but also, more specifically, in its biologic role and discusses the most recent applications of the drug in solid tumors, both at a preclinical and clinical level.

Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab The…

2022

N/A

Sealing ability of five different retrograde filling materials.

1996

The sealing ability of Amalgam, Harvard-Cement, Diaket, gold-leaf, and Ketac-Endo as retrofilling materials was investigated. Paper cones were fixed with Harvard-Cement in the instrumented roots of 100 extracted human incisors. Apicectomy was performed and a 2-mm-deep retrograde cavity was prepared. Teeth were assigned to five groups (n = 20); each group received a different filling material. Surfaces of the roots were isolated with nail polish. Teeth, were stored in 1% methylene blue dye for 72 h. Roots were sectioned, and the depth of dye penetration was evaluated through a stereomicroscope. Retrofills with Ketac-Endo showed significantly less leakage compared with amalgam. There was no s…

M. TULLI CICERONIS Topica, edidit, commentario critico instruxit G. Di Maria

1994

EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European…

2016

AIMS: To determine whether the Joint European Societies guidelines on cardiovascular prevention are being followed in everyday clinical practice of secondary prevention and to describe the lifestyle, risk factor and therapeutic management of coronary patients across Europe. METHODS AND RESULTS: EUROASPIRE IV was a cross-sectional study undertaken at 78 centres from 24 European countries. Patients <80 years with coronary disease who had coronary artery bypass graft, percutaneous coronary intervention or an acute coronary syndrome were identified from hospital records and interviewed and examined ≥ 6 months later. A total of 16,426 medical records were reviewed and 7998 patients (24.4% female…